Last updated: March 2026
Cerebrolysin is a porcine brain-derived peptide mixture containing fragments of CNTF, GDNF, and NGF. With over 200 published clinical studies spanning stroke recovery, traumatic brain injury, and dementia, it is one of the most researched neurotrophic compounds available — approved in 40+ countries but not in the United States.
Cerebrolysin (FPF 1070) is a porcine brain-derived peptide mixture produced by EVER Neuro Pharma (Austria). Unlike single-peptide compounds, it contains a complex mixture of low-molecular-weight neuropeptides (1-10 kDa) that collectively mimic the effects of endogenous neurotrophic factors.
Contains peptide fragments including CNTF (ciliary neurotrophic factor), GDNF (glial cell line-derived neurotrophic factor), and NGF (nerve growth factor) fragments. The exact composition is complex — derived from porcine brain tissue through enzymatic hydrolysis, creating a mixture of biologically active peptides.
Produced by EVER Neuro Pharma (Austria) — a pharmaceutical company specializing in neurotrophic drugs. Cerebrolysin has been in clinical use since the 1950s, making it one of the oldest continuously used neurotrophic preparations in the world.
Derived from porcine (pig) brain tissue. This is both a benefit (rich source of mammalian neural peptides) and a controversy (prion concerns, religious/cultural restrictions). All batches undergo strict quality control for safety.
MUST be delivered via IV infusion or IM injection. Oral administration is completely ineffective — peptides would be digested in the gastrointestinal tract. This significantly limits accessibility compared to oral nootropics.
Cerebrolysin exhibits neurotrophic factor-like activity through multiple overlapping pathways. Rather than targeting a single receptor, it provides a cocktail of peptide fragments that collectively promote neuronal survival, plasticity, and function.
Key insight: Cerebrolysin doesn't work through a single mechanism — it's a multi-target neurotrophic preparation. The peptide mixture mimics the effects of BDNF and NGF while also providing neuroprotective, anti-excitotoxic, and anti-inflammatory effects.
The peptide fragments in Cerebrolysin mimic the effects of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These are the body's primary neurotrophins — proteins that support neuron survival, growth, and synaptic plasticity.
Reduces excitotoxic damage from glutamate overload, decreases amyloid-beta toxicity (relevant to Alzheimer's), promotes neuronal survival under hypoxia, and modulates neuroinflammation through cytokine regulation.
Promotes hippocampal neurogenesis (new neuron formation), enhances synaptic plasticity (the brain's ability to rewire), and improves cholinergic neurotransmission — a system critical for memory and learning.
Improves cerebral glucose metabolism and ATP production. Supports mitochondrial function in neurons, helping brain cells maintain energy production under stress or ischemic conditions.
Cerebrolysin has one of the largest clinical trial databases of any neurotrophic compound, with 200+ published studies. Most trials were conducted in Eastern Europe and Russia where the compound has been approved for decades.
Evidence context: The volume of research is impressive, but most trials come from Eastern European institutions with limited Western validation. Meta-analyses show generally positive trends, particularly for stroke and vascular dementia. The FDA has not approved Cerebrolysin, largely due to the lack of large-scale Western RCTs.
Cerebrolysin sits in an unusual regulatory position — widely approved internationally but not in the US or UK. Understanding why is important for anyone considering this compound.
Approved in Russia, China, Japan, South Korea, most of Eastern Europe, and many other countries for stroke, TBI, and dementia treatment. Has been used clinically since the 1950s in some regions.
Not approved by the FDA in the United States. Not available in US pharmacies. This is the primary barrier for American patients seeking treatment.
Multiple factors: (1) Limited large-scale Western RCTs, (2) Porcine source creates regulatory complexity, (3) IV/IM administration vs. oral drugs, (4) FDA typically requires US-based trials. Not a safety issue — a regulatory pathway issue.
In countries where it's approved, Cerebrolysin requires a prescription and must be administered by medical professionals. It's not an over-the-counter supplement — it's a pharmaceutical.
Cerebrolysin dosing is standardized based on clinical protocols from published studies. All administration requires medical supervision.
10-30mL per day, depending on indication. The typical therapeutic dose is 20mL daily for most conditions. Administered via IV infusion (preferred) or IM injection.
20-30mL daily for acute ischemic stroke, typically started within 48 hours of the event. Initial course: 10-15 daily infusions. Must be administered in a clinical setting with monitoring.
| Condition | Daily Dose | Duration | Notes |
|---|---|---|---|
| Ischemic Stroke | 20-30mL | 10-15 days | Start within 48 hours |
| TBI | 20mL | 10-20 days | Based on severity |
| Vascular Dementia | 20mL | 20-30 days | Repeat courses possible |
| Alzheimer's | 10-30mL | 20+ days | Longer courses common |
Cerebrolysin is generally well-tolerated across the large clinical trial database. Most side effects are mild and transient.
Based on clinical evidence and approved uses, here are the profiles of who Cerebrolysin is most appropriate for.
Cerebrolysin exists in a controversial space — respected scientifically but questioned regulatorily. Here's what you need to know.
The porcine brain source raises theoretical prion disease (like Creutzfeldt-Jakob) concerns. However, EVER Neuro Pharma uses specific manufacturing processes to inactivate prion proteins. No cases of prion transmission have ever been documented from Cerebrolysin use.
The FDA has not approved Cerebrolysin. This doesn't mean it's unsafe — it means the FDA hasn't reviewed the specific data package submitted. Many effective treatments are approved internationally but not in the US.
Most trials come from Eastern Europe with smaller sample sizes. While the total volume is large (200+ studies), the quality varies. Large-scale Western RCTs are limited, making definitive conclusions harder.
IV/IM administration means it's not a simple supplement. Requires prescription, medical supervision, and clinical visits. This significantly limits who can realistically use it.
Note: Swiss Chems does not currently carry Cerebrolysin as it requires injection and prescription. For other cognitive compounds, browse the nootropics selection.
Affiliate links — supports MeetPeptide research content at no extra cost.
Support supplements if pursuing Cerebrolysin therapy (must be prescribed). These support brain health generally.
Affiliate links help support MeetPeptide at no extra cost to you.
Cerebrolysin is NOT FDA approved in the United States and is not available in US pharmacies. It requires a prescription and must be administered by medical professionals via IV or IM injection. This page is for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Not Available in USApproved 40+ CountriesPrescription Required